pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog
← back to Ultragenyx Pharmaceutical Inc.
News mentioning $RARE
1,152
stories
5d
STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
stat
5d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
5d
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
stat
5d
Senator-elect Abdul El-Sayed on restoring trust in science, the state of public health, and RFK Jr.
stat
6d
FDA warns Chinese API manufacturers for refusing records requests, quality oversight
raps
6d
This Week: Senate HELP to vote on Overton, FDA shelves CNPV, and more
raps
6d
Sofinnova books biggest-ever $815M fund with an eye toward up-and-coming ‘global leaders’
fiercebiotech
6d
Deep dive: Cardiovascular calamities and catalysts
biospace
6d
STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment
stat
6d
FDA’s commissioner voucher program reportedly shuttered ahead of Senate vote on Overton
biospace
7d
10 companies hiring in New Jersey
biospace
7d
Why a fresh approach to targeting G protein-coupled receptors could treat a rare eye cancer
fiercebiotech
7d
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
stat
7d
PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
biospace
7d
Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
biospace
7d
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
biopharma dive
7d
Merck KGaA lands FDA nod for joint tumor drug it licensed from Abbisko
endpoints
7d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
7d
A new tactic in the war over out-of-network bills: Health care providers are suing employers
stat
7d
STAT+: Doctors on Kennedy’s influential preventive care panel have major conflicts of interest, filings reveal
stat
7d
STAT+: MDCalc launches a ‘rumble strip’ for doctors using generative AI tools
stat
7d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
8d
PepGen soars on promising early data for muscular dystrophy drug
biopharma dive
8d
FDA's rare disease framework faces its first real test in Capricor’s DMD drug
biospace
8d
STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care
stat
8d
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
biospace
8d
STAT+: GLP-1s are given an FDA warning for rare eye condition risk
stat
8d
Delix raises $100M to advance at-home psychedelic without hallucinogenic effects
biospace
8d
Delix raises $100M to advance at-home psychedelic without hallucinatory effects
biospace
8d
STAT+: Pharmalittle: We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
stat
← prev
page 2 of 39
next →